Medical Health & Life Science Research News

New report examines the human cytomegalovirus envelope glycoprotein B therapeutic pipeline H1 2017

Covering key players Astellas Pharma Inc, Novartis AG, Trellis Bioscience Inc

- Advertising -

Summary

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017

Request a sample report @ www.htfmarketreport.com/sample-rep…pe-glycoprotein-b

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity.

It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell.

- Advertising -

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 1, 1 and 4 respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Female Contraception, Glioblastoma Multiforme (GBM), Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2017, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

Companies Mentioned in the Report

Astellas Pharma Inc

Novartis AG

Trellis Bioscience Inc

Vakzine Projekt Management GmbH

VBI Vaccines Inc

Vical Inc

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)

- The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects

- The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Access this report @ www.htfmarketreport.com/buy-now?fo…amp;report=498336

Reasons to access

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get report @ www.htfmarketreport.com/request-di…pe-glycoprotein-b

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Novartis AG

Trellis Bioscience Inc

Vakzine Projekt Management GmbH

VBI Vaccines Inc

Vical Inc

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles

ASP-0113 - Drug Profile

Product Description

Mechanism Of Acti

....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/49…pe-glycoprotein-b

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany profile: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...